Fish defense mechanism may reveal fatty liver disease therapeutic target
A possible therapeutic target for fatty liver disease (FLD) has been identified by researchers studying the natural defense mechanisms of certain cave-dwelling fish. While…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
Resmetirom, now Rezdiffra, is 1st therapy approved for NASH in US
The U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) for the treatment of people with noncirrhotic nonalcoholic steatohepatitis (NASH) — a severe type…
Livmarli’s long-term benefits in Alagille extend beyond itch: Study
Up to six years of treatment with Livmarli (maralixibat), which is approved for reducing itch, or pruritus, in Alagille syndrome, prolonged survival and…
Many viruses behind 2022 outbreak of hepatitis in children: Study
A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by infections with multiple viruses at…
Seladelpar found to reduce disease activity, itch in PBC patients in trial
Daily treatment with seladelpar, CymaBay Therapeutics’ investigational oral candidate for people with primary biliary cholangitis (PBC), was shown to normalize liver biomarkers and…
Websites of transplant centers in US stigmatize ALD with word choice
Most liver transplant centers in the U.S. continue to use stigmatizing language on their websites that could make people with alcohol-associated liver disease (ALD)…
Bexotegrast shows positive signs as PSC treatment in Phase 2 trial
Pliant Therapeutics’ investigational oral treatment bexotegrast safely eases itching and is associated with signs of better liver function and less liver scarring, or fibrosis, in…
Bile acids stay high in biliary atresia patients after Kasai procedure
Bile acids, which aid the fat-digesting functions of bile fluid, remain elevated in the blood and urine of adult biliary atresia patients whose bile…
Tirzepatide for weight loss treats fatty liver disease in Phase 2 trial
Weekly injections of tirzepatide, an approved obesity and diabetes treatment, showed promise in people with nonalcoholic steatohepatitis (NASH) — now known as metabolic dysfunction-associated steatohepatitis…
Antiviral duo found effective for hepatitis E despite virus mutations
A combination of the antiviral medications ribavirin and sofosbuvir efficiently cleared the hepatitis E virus (HEV) from two chronically infected patients despite the emergence of…